Prediction of drug adverse event through gene expression analysis

Prediction of drug adverse event through gene expression analysis - Prediction of drug adverse event through gene expression analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000672

Enrollment

Registered

2007-04-05

Start date

2007-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

embedded dens molaris

Interventions

Cefcapene Pivoxil Hydrochloride Hydrate 100mg po administration for three times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: those who are planned to receive exodontics of one of embedded third dens molaris

Exclusion criteria

Exclusion criteria: renal dysfunction (Creatinin equal or greater than 2.0 mg/dl) liver dysfunction (ALT, AST, T-bil, LDH or ALP are more than two times greater than upper limit of normal range) confirmed or clinically suspected myocardial infarction and/or congestive heart failure prescribed medicines for diabetes mellitus and/or hypertension pasthistory for hypersensitivities and/or allargic reactions against Cefcapene Pivoxil Hydrochloride Hydrate or ingredients of Flomox(R) Past history of hypersensitivities for Cephalosporins

Design outcomes

Primary

Measure	Time frame
correlation and differences of gene expression between results from basic experiments in vitro and ones in human	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026